Company intelligence / Profile preview

BG Medicine

Waltham, Massachusetts, United Statesbg-medicine.com ↗

Ownership: Private
Development stage: Commercial

Overview

BG Medicine developed molecular diagnostic tests focused on cardiovascular disease. Its lead product, the Galectin‑3® blood test, received FDA approval to help predict outcomes in chronic heart failure patients. The company also developed CardioSCORE, a multi-analyte biomarker blood test for assessing near-term risk of major cardiovascular events. The Galectin‑3® test was sold in the US and Europe through partnerships with major diagnostics companies including Abbott, BioMerieux, and Siemens.

Therapeutic areas: Cardiovascular
Modalities: Diagnostic test (in vitro diagnostic device)Molecular diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

Galectin-3 blood test

Commercial

Indications: Heart failure

Partnerships

AbbottBioMerieuxSiemens

Beyond the preview

Go deeper on BG Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG Medicine.

Explore the full profile